Webinar | TiO₂ alternatives for food, pharma, and personal care Register Here

Kynexis

Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
2023
11-50
Naarden, Noord-Holland, The Netherlands
BiotechnologynologyHealth CareMedicalPrecision MedicineTherapeutics

Investment Funding

Last Funding Stage

Series A

Total Funding Amount

60.97M

Last Funding Amount

60.97M

Last Funding Date

07-11-2023

Startup Stage

Early Stage

Lead Investors

Ysios Capital, Forbion Capital Partners, Sunstone Life Science Ventures